Some of us know the data. Some don’t. The question once you do is where we go from here to bridge the gender inequality gap?
Welcome to The Catalyst
Change isn't quick. Unless it's when you experience Intravascular Lithotripsy (IVL) for the first time. Stay apprised of our latest news and insights while discovering how a simple and intuitive tool can be The Catalyst to change the way you think about calcium modification.
Some of us know the data. Some don’t. The question once you do is where we go from here to bridge the gender inequality gap?
Topics: Coronary IVL, IVL Technology, Coronary Clinical Data, Shockwave C2, Female vs. Male Outcomes
Discover our PCR webinar featuring European calcium experts, Prof Emanuele Barbato, Prof Javier Escaned, Dr Margaret McEntegart, and Prof Flavio Luciano Ribichini discussing about the most recent OCT data analysis from Disrupt CAD Trials.
Topics: Coronary IVL, IVL Technology, Coronary Clinical Data, Shockwave C2, Treating Different Ca++ Morphologies, Female vs. Male Outcomes
Prof. Javier Escaned, Hospital Universitario Clínico San Carlos, Madrid, and Prof. James Spratt, St George’s University Hospital NHS Trust, London, discussed with Cardiovascular News their views about the latest data from the pooled analysis of 262 patients enrolled in OCT sub-studies from Disrupt CAD I, II, III, & IV.
Topics: Coronary IVL, IVL Technology, Shockwave C2, Treating Different Ca++ Morphologies
Dr. Benjamin Honton, Interventional Cardiologist at Clinique Pasteur, Toulouse, France, together with Dr. Jacques Monsegu, Groupe Hospitalier Mutualiste de Grenoble, France, write about best practices for IVL use in the cath lab based on his 3 years of experience with the technology. In this review you will find IVL technical, scientific and clinical overview, such as lesion selection with focus on concentric and eccentric calcification, analysis of specific clinical indications and some useful tips for crossing and therapy delivery.
Topics: Coronary IVL, IVL Technology, Shockwave C2, Treating Different Ca++ Morphologies
Based on Shockwave’s recognition on Fast Company’s 2022 list of the World’s Most Innovative Companies in the medical device sector for “bringing good vibrations to heart procedures,” we sat down with Shockwave CEO Doug Godshall for a Q&A to discuss how innovation is fostered at SWAV and why continual innovation is imperative to the future success of the company.
You can also read more about the honor in the company’s press release, in which Doug is quoted saying, “Shockwave Medical was founded with innovation at our core…not only for pioneering revolutionary and proprietary IVL technology, but also for the ways that innovation permeates every aspect of our business. We are continually evolving and transforming how we do things as we seek to astound our customers with life changing products for the treatment of calcified cardiovascular disease.”
Topics: Coronary IVL, Peripheral IVL, IVL Technology, SWAV News, ChalkTalk Podcast
Disrupt CAD Pooled Gender Analysis is now in published in JSCAI - the new journal of the Society for Cardiovascular Angiography & Interventions. Read the JSCAI publication here: https://www.jscai.org/article/S2772-9303(21)00011-9/fulltext
Topics: Coronary IVL, IVL Technology, Coronary Clinical Data, Shockwave C2, Female vs. Male Outcomes
The one-year Disrupt CAD III data has been published in JSCAI – the new journal of the Society for Cardiovascular Angiography & Interventions. The new data from Disrupt CAD III confirm the consistency of the excellent safety and effectiveness outcomes at 30 days out to one year.
Topics: Coronary IVL, IVL Technology, Coronary Clinical Data, Shockwave C2
2021 was Shockwave’s best year yet! Although it brought challenges, with it came immense opportunities which allowed us to grow and exceed expectations. As we push on into 2022, we are excited for what the year will bring but most importantly, for the opportunities to continue to help improve patient outcomes across the globe. But before we get started, let’s review the highlights of last quarter. We released four data releases, including our 1-year results of our Coronary IVL pivotal study at TCT this year, making it a monumental event. We had some exciting peer-reviewed publications come out, enrolled the first patient in the Disrupt BTK II Study, and much more. Read the latest PulsePoint for all the updates!
Topics: Coronary IVL, Peripheral IVL, IVL Technology, PulsePoint Newsletter
For the first time, Shockwave Medical participated in ASIA-PCR, which was entirely virtual because of the ongoing COVID-19 pandemic. Watch our joint symposium with Abiomed entitled: “THE CHALLENGES OF COMPLEX PCI TREATMENT: Mechanical support in CHIP patients and IVL for calcified coronary disease”.
Topics: Coronary IVL, IVL Technology, Shockwave C2
In the latest ChalkTalk podcast, we’re going to listen in on a sponsored discussion that took place with TCTMD during TCT21 about new insights on the latest Coronary IVL data that was presented during the meeting with Drs. Ajay Kirtane, Alexandra Lansky, Matthew Price, and Ziad Ali. Hope you enjoy the conversation and for more information on the data, please visit LetsGetCracking.com.
Topics: Coronary IVL, IVL Technology, SWAV News, ChalkTalk Podcast, Treating Different Ca++ Morphologies, Female vs. Male Outcomes
But, right now we're in the early phases of the R&D program. In the meantime, don't miss the IVL application that heart teams are embracing already — maintaining transfemoral TAVR access through heavily calcified iliacs by using IVL.
